Navigation Links
BioGenex Introduces PD1 and PDL-1 Antibodies for Immunohistochemistry (IHC)
Date:3/8/2017

FREMONT, Calif., March 8, 2017 /PRNewswire/ -- BioGenex, a global leader in molecular pathology announced introduction of monoclonal antibodies for the detection of immune checkpoint proteins: PD1 and PD-L1 by immunohistochemistry (IHC). The antibodies are CE marked and are also available for purchase in the US. The PD1 and PD-L1 antibodies can be used to determine the expression status of the target proteins in metastatic non-small cell lung cancer (NSCLC) using formalin fixed paraffin embedded tissues, and have been validated for use in manual assays or with BioGenex automated staining systems.

The Programmed Cell Death ligand 1 (PD-L1) protein is upregulated in various cancers including many cases of NSCLC lung cancer. Binding of PD-L1 to PD1 cell surface receptors on cytotoxic T cells inhibit the antitumor immune response thus promoting tumor growth and metastasis. Lung cancer is by far the leading cause of cancer death and is responsible for about 1 out of every 4 cancer deaths in the United States. The American Cancer Society's estimates about 222,500 new cases of lung cancer and about 155,870 deaths from lung cancer in the US for 2017. 80-85% of lung cancers are classified as NSCLC and are relatively insensitive to chemotherapy. During the past three decades, lung cancer has shown the least improvement in survival rates when compared with other cancers.

PD-L1 Antibody Staining in Human Tonsil Tissue Using DAB Chromogen
PD-L1 Antibody Staining in Human Tonsil Tissue Using DAB Chromogen
PD1 Antibody Staining in Human Tonsil Tissue Using DAB Chromogen
PD1 Antibody Staining in Human Tonsil Tissue Using DAB Chromogen

"These antibodies add to BioGenex growing portfolio of cancer biomarkers product line and reflect our commitment to provide the most advanced solutions for tumor diagnosis, clinical and life science research. Our advanced systems which include automation, detection kits, antibodies, reagents, consumables and optimized protocols provide a fully integrated Workflow Solution for Pathology labs around the world," said BioGenex CEO, Dr. Krishan Kalra.

BioGenex offers over 400 antibodies for IHC.  We are committed to continue to expand our molecular pathology product portfolio. Read more or call (800)-421-4149 to order.

About BioGenex:  BioGenex designs, develops and commercializes molecular pathology systems for cancer diagnosis, prognosis, precession medicine and life science research. The recent introduction of our cytogenetic FISH workflow solution and miRNA system for characterization of Cancer of Unknown Primary (CUP) and undifferentiated tumors are a game changer and envy of the industry. Our fully-automated molecular pathology workstations are the most advanced system available globally. BioGenex prides itself on delivering cutting edge technology, years ahead of its competition, providing the finest systems for immunohistochemistry (IHC), In Situ hybridization (ISH), FISH, Special stains and in situ PCR. BioGenex unconditionally guarantees performance of its systems and products: antibodies, probes, antigen retrieval, detection systems and histology stains. We are committed to provide quality systems and best in class customer care.  

www.biogenex.com

Corporate Communication
Dr. Krishan Kalra, BioGenex Founder and CEO
BioGenex
800-421-4149
149365@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biogenex-introduces-pd1-and-pdl-1-antibodies-for-immunohistochemistry-ihc-300420120.html


'/>"/>
SOURCE BioGenex
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. A Novel, Quantitative Immunohistochemistry Method Enabled by BioGenex IHC System
2. BioGenex Boosts Genome Research and Diagnostics with the Launch of the Xmatrx Mini for Simplified FISH, ISH, and In Situ PCR Analysis of Histology and Cytology Specimens
3. BioGenex Launches Two New Antibodies for Cancer Diagnosis
4. BioGenex Will Introduce Fully Integrated miRNA-ISH System for Tumor Diagnosis and Clinical Research at the USCAP Annual Meeting in Seattle, WA
5. BioGenex Launches the Integrated eFISHiency System for the Analysis of Solid Tumors and Hematological Malignancies with Streamlined & Simplified Protocol
6. BioGenex Completes Construction of a State-of-the-Art Center for Cancer Diagnostics and Molecular Pathology Innovation in Hyderabad, India
7. TeleHealth Medical Group Introduces World’s First Guaranteed Rehabilitation Program for Stroke Victims
8. Exxact Introduces New Spectrum Development Workstation Featuring NVIDIA Quadro GP100 and NVLink Technology
9. Cryoport Introduces CryoStork Next Flight Out Cryogenic Logistics Solution for the Reproductive Health Market
10. OHAUS Introduces the New Starter 3100M
11. Aerocom Healthcare Introduces Chain-of-Custody Pneumatic Tube System at ASHP Midyear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):